OptiLab NVeCam: A Breakthrough in Cervical Cancer Early Detection

Poltekkes Kemenkes Yogyakarta

2025-03-05

eng

info:eu-repo/semantics/article

application/pdf

Cervical cancer is the third leading cause of cancer related deaths worldwide. death in all cancer cases in the world. Screening for cervical cancer can help prevent it, with methods like Visual Inspection with Acetic Acid (VIA). The VIA examination has traditionally been conducted visually, without the aid of tools, leading to subjective results and a lack of documentation of examination outcomes. Digital technologies such as the “OptiLab NVeCam” aid in VIA implementation. This study aims to evaluate the impact of the ” OptiLab NVeCam” on VIA accuracy. It employs a quasi-experimental design with a single-group pre-post test conducted in Java in 2022, involving 71 midwives who perform VIA. The study utilized accidental sampling and analyzed via the Wilcoxon test. Results indicate significant improvement in VIA accuracy using the Digital Colposcope among midwives (p = 0.008). Furthermore, VIA results obtained with the ” OptiLab NVeCam ” was consistent with validator, demonstrating its efficacy and accuracy in cervical cancer screening. he introduction of ” OptiLab NVeCam ” addresses these issues in VIA examinations, offering a solution for more accurate and documented screening outcomes.